|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003015,
umls-concept:C0008976,
umls-concept:C0018801,
umls-concept:C0026538,
umls-concept:C0026565,
umls-concept:C0031809,
umls-concept:C0178602,
umls-concept:C0301630,
umls-concept:C0439849,
umls-concept:C0717550,
umls-concept:C0814225,
umls-concept:C1524062,
umls-concept:C1706907
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-4-28
|
|
pubmed:abstractText |
Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:CHARM Investigators,
pubmed-author:DunlapMark EME,
pubmed-author:EarleStevenS,
pubmed-author:GrangerChristopher BCB,
pubmed-author:HainerJamesJ,
pubmed-author:McMurrayJohn J VJJ,
pubmed-author:MichelsonEric LEL,
pubmed-author:OlofssonBertilB,
pubmed-author:OstergrenJanJ,
pubmed-author:PfefferMarc AMA,
pubmed-author:SwedbergKarlK,
pubmed-author:YoungJames BJB,
pubmed-author:YusufSalimS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
151
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
985-91
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16644319-Aged,
pubmed-meshheading:16644319-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:16644319-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:16644319-Benzimidazoles,
pubmed-meshheading:16644319-Dose-Response Relationship, Drug,
pubmed-meshheading:16644319-Drug Therapy, Combination,
pubmed-meshheading:16644319-Female,
pubmed-meshheading:16644319-Heart Failure,
pubmed-meshheading:16644319-Hospitalization,
pubmed-meshheading:16644319-Humans,
pubmed-meshheading:16644319-Male,
pubmed-meshheading:16644319-Middle Aged,
pubmed-meshheading:16644319-Proportional Hazards Models,
pubmed-meshheading:16644319-Randomized Controlled Trials as Topic,
pubmed-meshheading:16644319-Tetrazoles
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
|
|
pubmed:affiliation |
Department of Cardiology, Western Infirmary, Glasgow, Scotland. j.mcmurray@bio.gla.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
